Sofinnova Partners
Fondsmanagerprofil und erfasste Fonds.
Alle Zahlen umfassen die hier seit 1. Januar 2025 erfassten europäischen Fonds, abgeschlossen oder noch im Fundraising, und stammen aus öffentlichen Quellen.
- Erfasste Fonds
- 4
- Erfasstes Volumen
- €1,622m
- Neueste Quelle veröffentlicht
- November 2026
Das erfasste Volumen summiert die hier erfassten öffentlichen Fondsbeträge, nicht das gesamte verwaltete Vermögen des Managers. Es kann daher von Angaben auf dessen Website abweichen.
Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare and sustainability. It invests from seed through later stages.
Fokus: Life sciences, healthcare and sustainability, from seed to later stage
In 2021, Sofinnova said its €445m Crossover Fund was Europe's largest dedicated fund for late-stage biopharma and medtech scale-ups (company statement).
Erfasste Fonds
Late-stage life sciences crossover fund backing clinical-stage biopharma and medtech companies, about 15 companies, primarily in Europe.
- Health & Bio
- Primarily Europe, selective investments in the US and other markets
- Fonds 2
- November 2026
Biotech accelerator creating and backing European biotechs
- Health & Bio
- Europe
- Fonds 2
- März 2025
Flagship early-stage biotech and medtech fund
- Health & Bio
- Europe, North America
- Fonds 11
- November 2025
Medtech company creation: launch six to eight companies across Europe and the US over five years; support from inception through key clinical and operational milestones with capital and hands-on operational support.
- Health & Bio
- Europe; United States
- Fonds 4
- September 2026
Fondsseiten
- Sofinnova Crossover IISofinnova Partners · €725m reported · source published November 2026
- Sofinnova Biovelocita IISofinnova Partners · €165m reported · source published March 2025
- Sofinnova Capital XISofinnova Partners · €650m reported · source published November 2025
- Sofinnova MD Start IVSofinnova Partners · €82m reported · source published September 2026